Recently stock market analysts have updated their consensus ratings on shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/12/2016 – Aimmune Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 38 price target on the stock.

03/07/2016 – Aimmune Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 35 price target on the stock.

02/29/2016 – Wedbush began new coverage on Aimmune Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 42 price target on the stock.

08/31/2015 – Bank of America Merrill Lynch began new coverage on Aimmune Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 36 price target on the stock.

Aimmune Therapeutics, Inc. has a 50 day moving average of 13.68 and a 200 day moving average of 16.26. The stock’s market capitalization is 551.77M, it has a 52-week low of 12.43 and a 52-week high of 28.33.

The share price of the company (NASDAQ:AIMT) was up +2.19% during the last trading session, with a high of 13.14 and the volume of Aimmune Therapeutics, Inc. shares traded was 96623.

View other investors thoughts on Aimmune Therapeutics, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.